Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus

Journal of Diabetes Investigation

Volumn 8, Issue 4, 2017, Pages 416-427

  Kashiwagi, Atsunori ^a   Maegawa, Hiroshi ^b  

^a Kusatsu General Hospital   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Oral hypoglycemic drugs; Sodium glucose cotransporter 2 inhibitors; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; GLUCAGON; GLUCOSE; KETONE BODY; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION; GLUCAGON RELEASE; GLUCOTOXICITY; GLYCEMIC CONTROL; HEART PROTECTION; HEMODYNAMICS; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; SKIN PRURITUS; URINARY TRACT INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DRUG EFFECTS; KIDNEY PROXIMAL TUBULE; METABOLISM; PANCREAS; SECRETION (PROCESS);

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; KETONE BODIES; KIDNEY TUBULES, PROXIMAL; PANCREAS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85019198304     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12644     Document Type: Review

References (102)

1. +/glucose cotransporter SGLT2, Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994; 93: 397–404.
2. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011; 91: 733–794.
3. +/glucose cotransporter. J Biol Chem 1994; 269: 12032–12039
4. Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 2011; 32: 63–71.
5. Abdul-Ghani M, DeFronzo R, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes 2013; 62: 324–3328.
6. Isaji M. SGLT2 inhibitors: molecular design and potential differences in effect. Kidney Int 2011; 79(Suppl 120): S14–S19.
7. Kadokura T, Akiyama N, Kashiwagi A, et al. Pharmacokinetic and pharmaco dynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study. Diab Res Clin Pract 2014; 106: 50–56.
8. Sha S, Polidori D, Farrell K, et al. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study. Diabetes Obesity Metab 2015; 17: 188–197.
9. Sarashina A, Koiwai K, Seman LJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharamacokinet 2013; 28: 213–219.
10. Rosenwasser RF, Rosenwasser JN, Sutton D, et al. Tofogliflozin: a highly serective SGLT2 inhibitor for the treatment of type 2 diabetes. Drug of Today 2014; 50: 739–745.
11. Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. J Diabetes Investig 2014; 5: 265–275.
12. Yabe D, Nishikino R, Kaneko M, et al. Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. Expert Opin Drug Saf 2015; 14: 1–6.
13. Zinman B, Christoph W, Lachin JM, et al. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.
14. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323–334.
15. Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathway and review of on-going outcome trials. Diab Vasc Dis Res 2015; 12: 90–100.
16. Ferrannini G, Hach T, Crowe S, et al. Energy balance after sodium–glucose cotransporter 2 inhibition. Diabetes Care 2015; 38: 730–1735.
17. Kashiwagi A, Kazuta K, Yoshida S, et al. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig 2014; 5: 382–391.
18. Kashiwagi A, Kazuta K, Takinami Y, et al. Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study. Diabetol Int 2015; 6: 8–18.
19. List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650–657.
20. Kashiwagi A, Yoshida S, Nakamura I, et al. Efficacy and safety of ipragli-flozin in Japanese patients with type 2 diabetes stratified by body mass index: a subgroup analysis of five randomized clinical trials. J Diabetes Investig 2016; 7: 544–554.
21. Kashiwagi A, Akiyama N, Shiga T, et al. Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double blind, phase III EMIT study. Diabetol Int 2015; 6: 125–138.
22. Kashiwagi A, Kazuta K, Goto K, et al. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2015; 17: 304–308.
23. Kashiwagi A, Shiga T, Akiyama N, et al. Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study). Diabetol Int 2015; 6: 104–116.
24. Wilding JPH, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomized trial. Int J Clinical Pract 2013; 67: 1267–1282.
25. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941–950.
26. Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; 56: 2582–2592.
27. Nishimura B, Tanaka Y, Koiwai K, et al. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double blind, placebo-controlled, crossover study. Diabetes Obes Metab 2015; 17: 800–804.
28. Yamada A, Nakayama H, Yoshinobu S, et al. Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: a study using continuous glucose monitoring. J Diabetes Investig 2015; 6: 699–707.
29. Seino Y, Inagaki N, Haneda M, et al. Efficacy and safety of luseogliflozin added to various oral anti-diabetic drugs in Japanese patients with type 2 diabetes. J Diabetes Investig 2015; 6: 443–453.
30. Kohna DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014; 85: 962–971.
31. Yale J-F, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 2014; 16: 1016–1027.
32. Haneda M, Seino Y, Inagaki N, et al. Influence of renal function on the 52 week efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus. Clin Ther 2016; 38: 66–88.
33. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glyce mic control with metformin plus sulfonylurea. A 52-week randomized trial. Diabetes Care 2013; 36: 2508–2515.
34. Leiter LA, Yoon K-H, Arios P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care 2015; 38: 355–364.
35. Prato SD, Nauck M, Duran-Garcia S, et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulfonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab 2015; 17: 581–590.
36. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2013; 124: 499–508.
37. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014; 124: 509–514.
38. Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin. J Clin Invest 1987; 79: 1510–1515.
39. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990; 13: 610–630.
40. Cefalu WT. Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition. J Clin Invest 2015; 124: 485–487.
41. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015; 21: 512–517.
42. Polidori D, Mari A, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia 2014; 57: 891–901.
43. Takahara M, Shiraiwa T, Matsuoka T, et al. Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin. Endocrine J 2015; 62: 77–86.
44. Leiter LA, Forst T, Polidori D, et al. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab 2016; 42: 25–32.
45. McPherson PA, McEneny J. The biochemistry of ketogenesis and its role in weight management, neurological disease and oxidative stress. J Physiol Biochem 2011; 68: 141–151.
46. Laffel L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev 1999; 15: 412–426.
47. Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors. Predispose to Ketoacidosis. J Clin Endocrinol Metab 2015; 100: 2849–2852.
48. Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol 2014; 13: 65–80.
49. US Food and Drug Administration. Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood [Internet], 15 May 2015. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM446954.pdf Accessed June 22, 2015.
50. European Medicines Agency. Review of diabetes medicines called SGLT2 inhibitors started: risk of diabetic ketoacidosis to be examined [Internet], 12 June 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors_20/Procedure_started/WC500187926 Accessed June 12, 2015.
51. Erondu N, Desai M, Ways K, et al. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 2015; 38: 1680–1686.
52. Rosenstock J, Ferrannini E. Euglycemic Diabetic Ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015; 38: 1638–1642.
53. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium–glucose cotransporter 2 inhibition. Diabetes Care 2015; 38: 1687–1693.
54. Hayami T, Kato Y, Kamiya H, et al. Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low carbohydrate diet. J Diabetes Investig 2015; 6: 587–590.
55. Ministry of Health, Labor, and Welfare, Japan. Patient Survey. 2011 (Disease and Injury) (Japanese). Available at: http://www.mhlw.go.jp/toukei/saikin/hw/kanja/10syoubyo Accessed April 2015.
56. Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015; 313: 603–615.
57. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–713.
58. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 2014; 8: 330–339.
59. Lambers Heerspink HJ, de Zeeuw D, Wie L, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013; 15: 853–862.
60. Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015; 38: 420–428.
61. Kashiwagi A, Yoshida S, Kawamura K, et al. Effects of ipragliflozin, a selective sodium–glucose co-transporter 2 inhibitor on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials. Diabetol Int 2017; 8: 76–86.
62. Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014; 8: 262–275.
63. Sha S, Polidori D, Heise T, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2016; 16: 1087–1095.
64. Maliha G, Townsend RR. SGLT2 inhibitors: their potential reduction in blood pressure. J Am Soc Hypertens 2015; 9: 48–53.
65. Majewski C, Bakris GL. Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care 2015; 38: 429–430.
66. Kimura G. Importance of inhibiting sodium-glucose cotransporter and its compelling indicator in type 2 diabetes: pathophysiological hypothesis. J Am Soc Hypertension 2016; 10: 271–278.
67. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020–1031.
68. Wilding JP, Norwood PT, Joen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009; 32: 1656–1662.
69. Moses RG, Colagiuri S, Pollock C. SGLT2 inhibitors: new medicines for addressing unmet needs in type 2 diabetes. Australas Med J 2014; 7: 405–415.
70. Yokote K, Terauchi Y, Nakamura I, et al. Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study. Expert Opin Pharmacother 2016; 17: 1995–2003.
71. Nauck MA, Del Prato S, Meier U, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015–2022.
72. Lu C-H, Min KW, Chuang L-M, et al. Efficacy, Safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: results of phase 3 randomized placebo-controlled, double-blind, multicenter trial. J Diabetes Investig 2016; 7: 366–373.
73. Dailey G. Empagliflozin for the treatment of type 2 diabetes mellitus: an overview of safety and efficacy based on phase 3 trials. J Diabetes 2015; 7: 448–461.
74. Gavin JR III, Davies MJ, Davies M, et al. The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin 2015; 31: 1693–1702.
75. Hirji I, Andersson SW, Guo Z, et al. Incidence of genital infection among patients with 2 diabetes in the UK General Practice Research Database. J Diabetes Complications 2012; 26: 501–505.
76. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–1589.
77. The Diabetes Control and Complications Trial/Epidemiology of Diabetes. In terventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563–2569.
78. Gerstein HC, Miller ME, Byington RP, et al. Action to control cardiovascular risk in diabetes study group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–2559.
79. Fitchett D, Zinman B, Christone W, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J 2016; 37: 1526–1534.
80. Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 2014; 35: 391–404.
81. Kimura G. Diuretic action of sodium-glucose cotransporter 2 inhibitors and its importance in the management of heart failure. Circ J 2016; 80: 2277–2281.
82. Ferrannini E, Mark M, Mayoux E. CV protection in EMPA-REG OUTCOME trial: A “thrifty substrate”. Diabetes Care 2016; 39: 29–35.
83. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis Diabetes Care 2016; 39: 36–43.
84. Sato K, Kashiwaya Y, Keon CA, et al. Insulin, ketone bodies, and mitochondrial energy transduction. FASEB J 1995; 9: 651–658.
85. Balasse EO, Fery F. Ketone body production and disposal: effects of fasting, diabetes, and exercise. Diabetes Metab Rev 1989; 5: 247–270.
86. Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 2016; 65: 1190–1195.
87. Lommi J, Kupari M, Koskinen P, et al. Blood ketone bodies in congestive heart failure. J Am Coll Cardiol 1996; 28: 665–6729.
88. Janardhan A, Chen J, Crawford PA. Altered systemic ketone body metabolism in advanced heart failure. Tex Heart Inst J 2011; 38: 533–538.
89. Brenner BM, Cooper ME, deZeew D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.
90. Fioretto P, Dodson PM, Ziegler D, et al. Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol 2010; 6: 19–25.
91. Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 2014; 306: F194–F204.
92. Skric M, Yang GK, Perkins BA, et al. Characterization of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 2014; 57: 2599–2602.
93. Cherney DZ, Perkins BA, Soleymalon N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129: 587–597.
94. Korner A, Ekiof AC, Celsi G, et al. Increased renal metabolism in diabetes. Mechanism and functional implications. Diabetes 1994; 43: 629–633.
95. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17: 17–25.
96. 2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol 2015; 309: F227–F234.
97. Cahill GF Jr. Fuel metabolism in starvation in starvation. Ann Rev Nutr 2006; 26: 1–22.
98. Guder WG, Wagner S, Wirthensohn G, et al. Metabolic fuels along the nephron: pathways and intracellular mechanisms of interaction. Kidney Int 1986; 29: 41–45.
99. Shimazu T, Hirschey MD, Newman J, et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 2013; 339: 211–214.
100. Greene SJ, Gheorghiade M, Vaduganathan M, et al. Hemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail 2013; 15: 1401–1411.
101. Sano M, Takei M, Shiraishi Y, et al. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res 2016; 8: 844–847.
102. Kaku K, Maegawa H, Tanizawa Y, et al. Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study. Diabetes Ther 2014; 5: 415–433.